Development of standardized immunoassays and virus panels for HCV vaccine research
开发用于 HCV 疫苗研究的标准化免疫测定和病毒组
基本信息
- 批准号:10456321
- 负责人:
- 金额:$ 54.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-23 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAntibodiesAntibody ResponseAntibody titer measurementAntigensBiological AssayCellsDataDevelopmentGenerationsGenetic PolymorphismGenetic VariationGenotypeGlycoproteinsHepatitis C AntibodiesHepatitis C VaccineHepatitis C virusImmuneImmune PlasmaImmunoassayIndividualInfectionLaboratoriesLaboratory ResearchMeasurementMeasuresPhenotypePlayPreparationReagentReproducibilityRoleStandardizationVaccinationVaccine ResearchVaccinesValidationVariantViral AntigensVirusadaptive immune responsebaseenv Gene Productshuman subjectimprovedneutralizing antibodyneutralizing monoclonal antibodiesnovelpandemic diseasevaccine candidatevaccine developmentvirus envelope
项目摘要
Project Summary
Given the ongoing hepatitis C virus (HCV) pandemic, HCV vaccine development is an urgent priority.
Despite the extraordinary genetic diversity of the virus, some antibodies are broadly neutralizing, meaning that
these antibodies are able to block infection by genetically diverse HCV isolates. Stimulation of broadly
neutralizing antibodies is likely to be a major component of a protective HCV vaccine, so accurate and
standardized measurement of antibody titers and neutralization breadth is key to accelerating HCV vaccine
development. However, there is currently no standard assay or panel of HCV envelope proteins or viruses used
to measure antibody titers or neutralization.
We propose here to develop pure HCV antigens and a standardized immunoassay for quantification of
anti-HCV antibody responses to vaccination, and to develop a standardized HCV neutralization panel with
genetically and phenotypically diverse viruses for quantification of neutralizing antibody responses to
vaccination. These reference panels could be adopted as a standard for measurement of antibody titers and
neutralizing breadth, which would allow meaningful comparisons of results obtained in different laboratories,
and more rapid advancement of HCV vaccine development.
Development of an HCV vaccine is an urgent priority. Accurate and standardized measurement of the
titers, neutralizing potency and breadth of antibodies using diverse HCV isolates is key to evaluating HCV
vaccine candidates and comparing results obtained in different laboratories. By generation of pure HCV antigens,
a standardized immunoassay, and a standardized neutralization panel, we will facilitate accurate, reproducible
measurements of antibody responses, and accelerate HCV vaccine development.
项目摘要
鉴于丙型肝炎病毒(丙型肝炎病毒)的持续流行,研发丙型肝炎疫苗是当务之急。
尽管病毒的遗传多样性非同寻常,但一些抗体具有广泛的中和作用,这意味着
这些抗体能够阻止基因多样化的丙型肝炎病毒分离株的感染。宽泛的刺激
中和抗体很可能是保护性丙型肝炎疫苗的主要成分,因此准确和
抗体滴度和中和广度的标准化测量是加速丙型肝炎疫苗的关键
发展。然而,目前还没有使用丙型肝炎病毒包膜蛋白或病毒的标准化验或试剂盒。
测定抗体效价或中和力。
我们建议建立一种用于定量检测丙型肝炎病毒的纯抗原和标准化免疫分析方法。
抗丙型肝炎病毒抗体对疫苗的反应,并开发标准化的丙型肝炎病毒中和小组
基因和表型不同的病毒用于定量中和抗体应答
接种疫苗。这些参照板可作为测量抗体效价的标准,并
中和广度,这将允许对不同实验室获得的结果进行有意义的比较,
而丙型肝炎疫苗的开发也更加快速推进。
开发丙型肝炎病毒疫苗是当务之急。准确、标准化的测量
使用不同的丙型肝炎病毒分离株的抗体效价、中和效力和广度是评估丙型肝炎病毒的关键
候选疫苗和比较在不同实验室获得的结果。通过产生纯的丙型肝炎病毒抗原,
标准化的免疫分析和标准化的中和面板,我们将促进准确、可重复性
测量抗体反应,并加快丙型肝炎病毒疫苗的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin Richard Bailey其他文献
Justin Richard Bailey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin Richard Bailey', 18)}}的其他基金
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
广泛中和抗 HCV 抗体的分子和结构表征
- 批准号:
10657917 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
The role of neutralizing antibodies in natural and treatment-induced control of hepatitis B with and without HIV-1 co-infection
中和抗体在自然控制和治疗诱导控制有或没有 HIV-1 合并感染的乙型肝炎中的作用
- 批准号:
10618760 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection
在有或没有 HIV-1 合并感染的急性乙型肝炎自然控制过程中中和抗体反应
- 批准号:
10402216 - 财政年份:2022
- 资助金额:
$ 54.2万 - 项目类别:
Neutralizing antibody responses during natural control of acute hepatitis B with and without HIV-1 coinfection
在有或没有 HIV-1 合并感染的急性乙型肝炎自然控制过程中中和抗体反应
- 批准号:
10674691 - 财政年份:2022
- 资助金额:
$ 54.2万 - 项目类别:
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans
抗体介导控制人类丙型肝炎病毒重复感染的机制
- 批准号:
10205733 - 财政年份:2021
- 资助金额:
$ 54.2万 - 项目类别:
Development of standardized immunoassays and virus panels for HCV vaccine research
开发用于 HCV 疫苗研究的标准化免疫测定和病毒组
- 批准号:
10172194 - 财政年份:2021
- 资助金额:
$ 54.2万 - 项目类别:
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans
抗体介导控制人类丙型肝炎病毒重复感染的机制
- 批准号:
10614981 - 财政年份:2021
- 资助金额:
$ 54.2万 - 项目类别:
Mechanisms of antibody-mediated control of repeated hepatitis C virus infection in humans
抗体介导控制人类丙型肝炎病毒重复感染的机制
- 批准号:
10398151 - 财政年份:2021
- 资助金额:
$ 54.2万 - 项目类别:
Development of standardized immunoassays and virus panels for HCV vaccine research
开发用于 HCV 疫苗研究的标准化免疫测定和病毒组
- 批准号:
10655523 - 财政年份:2021
- 资助金额:
$ 54.2万 - 项目类别:
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
广泛中和抗 HCV 抗体的分子和结构表征
- 批准号:
9478874 - 财政年份:2017
- 资助金额:
$ 54.2万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 54.2万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 54.2万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 54.2万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 54.2万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 54.2万 - 项目类别: